Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| EA5182 | ECOG-ACRIN | Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5191 | ECOG-ACRIN | A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA5221 | ECOG-ACRIN | A Randomized Phase III Trial of Chemo Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6134 | ECOG-ACRIN | DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6141 | ECOG-ACRIN | Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6174 | ECOG-ACRIN | STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab, a Phase III Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6183 | ECOG-ACRIN | A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6191 | ECOG-ACRIN | The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6192 | ECOG-ACRIN | A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA6194 | ECOG-ACRIN | Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study | Adult CIRB - Late Phase Emphasis | Available to Open |